Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.4K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.4K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

1.3K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.3K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.2K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.2K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

3.2K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of Genetically Rare Cord Blood Units Beyond Conventional Quality Metrics.

HLA·2026
Same author

The myotonic dystrophy type 1 drug development pipeline: 2026 Edition.

Drug discovery today·2026
Same author

Oleic Acid Levels in HSA<sup>LR</sup> Mouse Model of Myotonic Dystrophy Type 1.

International journal of molecular sciences·2026
Same author

Correction: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment.

Cell death & disease·2026
Same author

Correction: Investigating the role of EGFR signalling in muscle dystrophies: implications for Duchenne muscular dystrophy.

Cell death & disease·2026
Same author

Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of spinal muscular atrophy.

Experimental & molecular medicine·2026

Related Experiment Video

Updated: Feb 25, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

16.0K

Myotonic dystrophy: candidate small molecule therapeutics.

Piotr Konieczny1, Estela Selma-Soriano1, Anna S Rapisarda1

  • 1Department of Genetics and Interdisciplinary Research Structure for Biotechnology and Biomedicine (ERI BIOTECMED), Universitat de València, Valencia, Spain; Translational Genomics Group, Incliva Health Research Institute, Valencia, Spain; Joint Unit Incliva-CIPF, Valencia, Spain.

Drug Discovery Today
|August 7, 2017
PubMed
Summary

Myotonic dystrophy type 1 (DM1) treatments are being explored. This review covers small molecules, including those from computational design and drug repurposing, to combat DM1's toxic gene effects.

More Related Videos

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.4K

Related Experiment Videos

Last Updated: Feb 25, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

16.0K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.4K

Area of Science:

  • Neuromuscular Disorders
  • Molecular Biology
  • Pharmacology

Background:

  • Myotonic dystrophy type 1 (DM1) is a rare genetic disorder.
  • It stems from CTG repeat expansions in the DMPK gene.
  • Toxic DMPK transcripts disrupt gene expression and sequester key proteins like MBNL.

Purpose of the Study:

  • To review small molecule therapeutics for DM1.
  • To explore diverse drug discovery approaches for DM1.

Main Methods:

  • Literature review of small molecule therapies for DM1.
  • Analysis of approaches including computational design, high-throughput screening (HTS), and drug repurposing.
  • Examination of therapeutic gene modulation strategies.

Main Results:

  • Numerous small molecules have been investigated for DM1.
  • Successful strategies include rational drug design and repurposing existing drugs.
  • Therapeutic gene modulation also shows promise.

Conclusions:

  • Small molecules represent a promising therapeutic avenue for DM1.
  • A combination of discovery methods is advancing DM1 treatment options.
  • Further research into these molecules could alleviate DM1 pathology.